Meme Kanseri Genom Rehberli Tedavi Çalışması (BEAUTY)

Sade dilde özet

Bu çalışma (BEAUTY), invaziv meme kanseri hastalarında tümörün genom (genetik) analizine göre tedavi seçimini araştırıyor. En az 1,5 cm tümörü olan, doğrulanmış invaziv meme kanseri olan 18 yaş üstü hastalar dahil edilmiştir. Faz uygulanmayan gözlemsel bir çalışmadır ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

N/A

Durum

Tamamlandı

Sponsor

Mayo Clinic

Başlangıç

03.03.2012

Tahmini bitiş

31.12.2020

Ülkeler

United States

İlgili genler

Merkezler

• Scottsdale, United States
• Rochester, United States

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

* Age ≥18 years.
* Histological confirmation of invasive breast cancer.
* Confirmation of breast cancer lesion ≥ 1.5 cm in size by any clinical (physical examination measurement) or radiographic criteria (mammogram, ultrasound or MRI) in the ipsilateral breast.

  * Note: Benign breast disease, LCIS or DCIS in the contralateral breast is allowed. Contralateral invasive breast cancer is allowed if disease is of clinically lower stage and the higher stage lesion will be the study lesion for all biopsies and tissue samples.
  * Note: Disease in axilla only is not eligible.
  * Note: Patients that have a contraindication or inability to have an MRI may still be enrolled on study and not participate in the MRI at any of the study specific time points.
  * Note: For patients with bilateral disease the higher clinical stage disease will be the study lesion that will undergo study biopsies and tissue samples from surgery and the contralateral lesion will NOT undergo research biopsies and tissue samples.
* Men or women who are to begin neoadjuvant chemotherapy for treatment of Stage I-III Her 2 negative breast cancer with paclitaxel followed by either the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) or the combination of doxorubicin and cyclophosphamide (AC). OR Men or women who are to begin neoadjuvant chemotherapy for treatment of Stage I-III Her 2 positive breast cancer with paclitaxel followed by either the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) or the combination of doxorubicin and cyclophosphamide (AC). MC1137 Trastuzumab will be given concurrently with the taxane portion and can be given concurrently with FEC (but not AC) at the discretion of the medical oncologist.

  * Note: Her2 positive disease is defined to be: HER2 score of 3+ by IHC or HER2 gene amplification by FISH.
* Provide informed written consent.
* Willing to return to Mayo Clinic in Rochester, MN, Mayo Clinic in Arizona, or Mayo Clinic in Florida for imaging correlative, surgery, and follow-up.
* Willing to provide blood samples for correlative research purposes.
* Willing to provide tissue samples for correlative research purposes.
* ECOG Performance Status ≤ 2.

Exclusion Criteria:

* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.
* Other active malignancy ≤ 5 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.

  * Note: If there is a history or prior malignancy, they must not be receiving any other treatment for their cancer.
* Patients who are not planning to receive neoadjuvant chemotherapy.
* Biopsy proven Stage IV disease.
* Patients who are pregnant or nursing.